BiotechTube

MK-8291 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postherpetic Neuralgia

Conditions

Postherpetic Neuralgia

Trial Timeline

Mar 12, 2015 → Feb 29, 2016

NCT ID
NCT02336555

About MK-8291 + Placebo

MK-8291 + Placebo is a phase 1 stage product being developed by Merck for Postherpetic Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT02336555. Target conditions include Postherpetic Neuralgia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02336555Phase 1Completed

Competing Products

20 competing products in Postherpetic Neuralgia

See all competitors
ProductCompanyStageHype Score
QUTENZAAstellas PharmaApproved
85
KHK6188 + PlaceboKyowa KirinPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
77
Etoricoxib + PlaceboMerckApproved
85
ADL5747 + Placebo + PregabalinMerckPhase 2
52
MK0759MerckPhase 2
52
MK0686MerckPhase 2
52
Comparator: pregabalin + Comparator: Placebo (unspecified)MerckPhase 1
33
Lyrica (pregabalin) + PlaceboPfizerApproved
84
RN624 + RN624 + PlaceboPfizerPhase 2
51
T-62PfizerPhase 2
51
pregabalin + pregabalin/PF-00489791 + PlaceboPfizerPhase 2
51
PH-797804 + PlaceboPfizerPhase 2
51
Placebo + Pregabalin + Pregabalin + PregabalinPfizerPhase 3
76
pregabalinPfizerPhase 3
76
pregabalinPfizerApproved
84
T-62 Dose 1 + T-62 Dose 2PfizerPhase 2
51
HSK16149 20mg BID + HSK16149 40mg BID + Placebo BIDHaisco Pharmaceutical GroupPhase 3
74
LevetiracetamUCBPhase 2
49

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85